Home
Matti Narkia's Library tagged → View Popular
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy -- Sorrentino et al., 10.1161/CIRCULATIONAHA.108.836346 -- Circulation
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy.
Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U.
Circulation. 2009 Dec 21. [Epub ahead of print]
PMID: 20026785
doi: 10.1161/CIRCULATIONAHA.108.836346
Conclusions—HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important
Quality of HDL differs in diabetics but improves with niacin therapy - theheart.org
"Quality of HDL differs in diabetics but improves with niacin therapy
December 22, 2009 | Michael O'Riordan
Hannover, Germany - A small study published this week hints that the effects of HDL cholesterol differ in healthy patients from those with diabetes mellitus [1]. HDL cholesterol in individuals with diabetes has impaired endothelial protective functions compared with the HDL from healthy subjects, although treatment with extended-release niacin can improve these endothelial protective effects, according to researchers.
Publishing their findings online December 21, 2009 in Circulation, lead investigator Dr Sajoscha Sorrentino (Hannover Medical School, Germany) and colleagues write that because recent HDL-raising intervention studies have yielded mixed results, "circulating HDL-cholesterol levels alone likely do not represent an adequate measure of therapeutic efficacy, and indexes of HDL functionality are urgently needed for assessment of the potential of HDL-targeted therapies to exert vasoprotective effects."
Speaking with heartwire, senior investigator Dr Ulf Landmesser (University of Zürich, Switzerland), said the results have implications for clinical research.
"We have to understand that we can't look only at the HDL levels in the plasma, but we need to look at the quality," he said. "The quality of the HDL is not the same in different patients. This is very important for targeting HDL as a treatment. Second, niacin therapy is a promising way not only to raise HDL but also to improve the quality; it is a good treatment option, especially if the larger outcomes data are positive.""
Vitamin B Niacin Offers No Additional Benefit To Statin Therapy In Seniors Already Diagnosed With Coronary Artery Disease
"The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.
In tests on 145 Baltimore-area men and women with existing atherosclerosis, all over age 65, researchers found that after 18 months of drug therapy, reductions in arterial wall thickness were measurably no different between the half who took dual niacin-statin therapy and the rest who remained on statin therapy alone. "
Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population: Insights From the ARIC (Atherosclerosis Risk in Communities) Study -- Yang et al. 54 (25): 2388 -- J
Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population
Insights From the ARIC (Atherosclerosis Risk in Communities) Study
Yang EY et al.
J Am Coll Cardiol, 2009; 54:2388-2395,
doi:10.1016/j.jacc.2009.10.006
Conclusions: ARIC participants with elevated hs-CRP and low LDL-C had a CVD event rate of 1.57% per year over 6.9 years, similar to the CVD event rate noted in the JUPITER study placebo group (1.36% per year over 1.9 years). The association of hs-CRP ≥2.0 mg/l with increased CVD risk and mortality regardless of LDL-C provides us a simple method of using age and hs-CRP level for identifying higher risk individuals. (Atherosclerosis Risk in Communities study; NCT00005131)
Patients With High CRP And Normal LDL Have Long-Term Risk For Heart Disease, Stroke And Death
"New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death.
These findings, which will be published online today in the Journal of the American College of Cardiology (JACC), demonstrate that a very simple screening, age plus CRP, can identify individuals who may benefit from statin therapy.
"This study builds on results from the landmark JUPITER trial, which showed that statins can prevent heart disease in people with normal LDL-c, or bad cholesterol, and an increased level of CRP," said Dr. Christie Ballantyne, director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart & Vascular Center and last author on the study. "We have demonstrated that the cardiovascular disease event rates persist over time, validating that the risks identified in the JUPITER trial persist for nearly seven year"
NEJM -- Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M.
N Engl J Med. 2009 Nov 26;361(22):2113-22. Epub 2009 Nov 15.
PMID: 19915217
Conclusions This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima–media thickness when combined with a statin and that niacin is superior to ezetimibe. (ClinicalTrials.gov number, NCT00397657 [ClinicalTrials.gov] .
Low vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype 1 chronic hepatitis C - Wiley InterScience :: Journal :: Article PDF
Low vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype 1 chronic hepatitis C
Salvatore Petta et al.
Hepatology, Volume 9999 Issue 999A, Page NA. Published Online: 4 Dec 2009
DOI: 10.1002/hep.23489
Conclusions:
G1 CHC patients had low 25(OH)D serum levels, possibly due to reduced CYP27A1 expression. Low vitamin D is linked to severe fibrosis and low SVR on IFN-based therapy. (HEPATOLOGY 2010.)
Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease -- Erkkilä et al. 80 (3): 626 -- American Journal of Clinical Nutrition
Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease.
Erkkilä AT, Lichtenstein AH, Mozaffarian D, Herrington DM.
Am J Clin Nutr. 2004 Sep;80(3):626-32.
PMID: 15321802
Conclusions: Consumption of fish is associated with a significantly reduced progression of coronary artery atherosclerosis in women with coronary artery disease.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial : The Lancet
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
[No authors listed]
Lancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.
PMID: 10465168
Interpretation
Dietary supplementation with n-3 PUFA led to a clinically important and satistically significant benefit. Vitamin E had no benefit. Its effects on fatal cardiovascular events require further exploration
Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer -- Chan et al., 10.1200/JCO.2008.18.8938 -- Journal of Clinical Oncology
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.
J Clin Oncol. 2009 Aug 1;27(22):3577-83. Epub 2009 Jun 15.
PMID: 19528373
DOI: 10.1200/JCO.2008.18.8938
Conclusion: These data suggest that the relationship between circulating selenium levels at diagnosis and prognostic risk of prostate cancer is modified by SOD2 genotype and indicate caution against broad use of selenium supplementation for men with prostate cancer.
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. - Wiley InterScience :: Article :: HTML Full Text
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate.
Spruijt L, Naviaux RK, McGowan KA, Nyhan WL, Sheean G, Haas RH, Barshop BA.
Muscle Nerve. 2001 Jul;24(7):916-24.
PMID: 11410919
DOI: 10.1002/mus.1089
Peripheral neuropathy appears to be a common side effect during chronic DCA treatment, even with coadministration of oral thiamine. Nerve conduction should be monitored during DCA treatment.
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression - ScienceDirect - Metabolism
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD.
Metabolism. 2009 Sep 3
doi:10.1016/j.metabol.2009.07.029
Liver function was improved greatly in these patients by showing reduction of liver enzymes. Our results confirmed the activity of BBR on InsR in humans and its relationship with the glucose-lowering effect. Together with our previous report, we strongly suggest BBR as an ideal medicine for T2DM with a mechanism different from metformin and rosiglitazone.
Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Zeng XH, Zeng XJ, Li YY.
Am J Cardiol. 2003 Jul 15;92(2):173-6.
PMID: 12860219
doi:10.1016/S0002-9149(03)00533-2
Thus, berberine improved quality of life and decreased VPCs and mortality in patients with CHF.
Efficacy of Berberine in Patients with Type 2 Diabetes
Efficacy of berberine in patients with type 2 diabetes mellitus.
Yin J, Xing H, Ye J.
Metabolism. 2008 May;57(5):712-7.
PMID: 18442638
doi: 10.1016/j.metabol.2008.01.013.
Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism
In summary, that berberine is a potent oral hypoglycemic agent with modest effect on lipid metabolism. It is safe and the cost of treatment by berberine is very low. It may serve as a new drug candidate in the treatment of type 2 diabetes. However, this is a pilot study. The efficacy of berberine needs to be tested in a much larger population and characterized as a function of the known duration of the diabetes. Further studies are needed to evaluate the action of berberine on type 2 diabetes in other ethnic groups.
Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients. - Br J Nutr. 1999 Feb;81(2):133-7. (free full text PDF available)
Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients.
Romagnoli E, Caravella P, Scarnecchia L, Martinez P, Minisola S.
Br J Nutr. 1999 Feb;81(2):133-7.
PMID: 10450331
The results of the present study emphasize the importance of 25-hydroxyvitamin D measurement, and the need to increase vitamin D intake in Italy; foodstuff fortification and supplement use must be considered in order to prevent negative effects of vitamin D deficiency on skeletal integrity.
All hospitalized patients, both in summer and in winter,
are characterized by the highest prevalence of hypovitaminosis
D, especially the older patients. Medical
inpatients may be at risk for vitamin D deficiency,
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H.
J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15.
PMID: 19501932
CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.
Vitamin D levels associated with survival in lymphoma patients
"ScienceDaily (Dec. 5, 2009) - A new study has found that the amount of vitamin D in patients being treated for diffuse large B-cell lymphoma was strongly associated with cancer progression and overall survival. The results will be presented at the annual meeting of the American Society of Hematology in New Orleans.
Also, several recent reports have concluded that vitamin D deficiency is associated with poor outcomes in other cancers, including breast, colon and head and neck cancer. This is the first study to look at lymphoma outcome.
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. - Nat Med. 2004 Dec;10(12):1344-51.
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD.
Nat Med. 2004 Dec;10(12):1344-51. Epub 2004 Nov 7.
PMID: 15531889
doi:10.1038/nm1135
We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5' proximal section of the LDLR mRNA 3' untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine -- Zhang et al. 93 (7): 2559 -- Journal of Clinical Endocrinology & Metabolism
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G.
J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. Epub 2008 Apr 8.
PMID: 18397984
doi:10.1210/jc.2007-2404
Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
Hypercalcemia in advanced head and neck squamous cell carcinoma: prevalence and potential impact on palliative care. - [J Support Oncol. 2009 Sep-Oct] - PubMed result
Hypercalcemia in advanced head and neck squamous cell carcinoma: prevalence and potential impact on palliative care.
Alsirafy SA, Sroor MY, Al-Shahri MZ.
J Support Oncol. 2009 Sep-Oct;7(5):154-7.
PMID: 19831158
Selected Tags
Related Tags
Sponsored Links
Top Contributors
Groups interested in patients
Highlighter, Sticky notes, Tagging, Groups and Network: integrated suite dramatically boosting research productivity. Learn more »
Join Diigo